

Utility of the ACQUITY UPLC I-Class System and Ion Mobility in a Routine Workflow to Understand the Challenge of Analyzing Fluoroquinolone Antibiotic Residues

Michael McCullagh, Ramesh Rao, and Sara Stead Waters Corporation, Wilmslow, UK

APPLICATION BENEFITS

- Unique protomer collision cross section (CCS) values can be determined and used as an additional identification parameter in a routine screening workflow.
- Individual protomer spectra are generated along with proposed fragmentation pathways.
- The impact of matrix upon protomer ratios can be observed routinely using new ion mobility processing functionality within the UNIFI® Scientific Information System.
- The ACQUITY® UPLC® I-Class System can be used in conjunction with ion mobility as a development tool to generate more robust analytical methods.
- Ability to perform retrospective UPLC and ion mobility data review.

WATERS SOLUTIONS

ACQUITY UPLC I-Class System ACQUITY UPLC BEH C₁₈ Column SYNAPT[®] G2-S High Definition Mass Spectrometry[®] (HDMS[®]) System

MassLynx® MS Software

UNIFI Scientific Information System

KEYWORDS

Protomer, collision cross section, CCS, ion mobility, spectral cleanup

INTRODUCTION

Across many application areas, the applicability of ion mobility to small molecule analysis continues to increase, along with the understanding of how this technology can help address current analytical challenges. The reason, challenge, and methods of achieving successful fluoroquinolones analysis were briefly discussed in a previous application note, where we described the use of the ACQUITY UPLC I-Class System combined with ion mobility mass spectrometry to show how fluoroquinolone class of compounds can form protomers.¹⁻⁵ Identification and characterization of the protomers of fluoroquinolones can now be routinely screened for using Waters[®] UNIFI Scientific Information System. The software within UNIFI allows for the routine characterization of fragmentation pathways of the respective protomers to be visualized. In addition, it is possible to see the direct impact of the matrix upon protomer formation, and hence obtain a greater INSIGHT of the challenges of using MRM to perform residue analysis of fluoroquinolones.

Fluoroquinolones are a family of synthetic broad-spectrum antimicrobial agents that have been administered to livestock for different purposes, including the prevention and control of infections and for growth promotion. Due to concerns regarding the spread of resistant microorganisms in the human population, the U.S. Food and Drug Administration (U.S. FDA) introduced a ban on the use of enrofloxacin and ciprofloxacin in livestock production in September, 2005.⁷⁻⁹ The use of antibiotic growth promoting agents (AGPs) in animal husbandry has been forbidden in the European Union (EU) since 2006.¹⁰

This application note explores the use of routine screening with UPLC and ion mobility to identify multiple protonation sites and different fragmentation patterns within the fluoroquinolone class of antibiotics. It can be used as an important method development tool to support the unequivocal identification of fluoroquinolone antibiotics in crude tissue extracts. UPLC and ion mobility have been utilized to analyze crude extracts of porcine muscle tissue to determine the presence of antibiotic residues including the fluoroquinolone class.

EXPERIMENTAL

An	alytes:		Standards fluoroquinolones			
Ex	tracts:		Porcine tissue			
UF	LC cond	itions				
UP	LC system	1:	ACQUITY UPLC I-Class			
Column:			ACQUITY UPLC BEH C ₁₈ 1.7 μ m, 100 mm x 2.1 mm			
Со	lumn temp	0.:	40 °C			
Flc	w rate:		0.6 mL/min			
Mc	bile phase	e A:	Water (0.1% formic acid)			
Mc	Aobile phase B:		Acetonitrile (0.1% formic acid)			
Inj	ection volu	ime:	10 µL			
Gra	adient: <u>Time</u>					
	(<u>min</u>)	<u>%A</u>	<u>%B</u>			
	Initial	.0	5.0			
	1.00	95.0	5.0			
	8.00	5.0	95.0			
	9.00	95.0	5.0			

MS conditions

MS system:	SYNAPT G2-S
Ionization mode:	ESI+
Capillary voltage:	2.0 kV
Cone voltage:	25 V
Desolvation temp.:	550 °C
Reference mass:	Leucine enkephalin [M+H] ⁺ = 556.2766
Acquisition range:	50 to 1200 Da
Acquisition rate:	4 spectra/sec
Collision energy:	15 to 45 eV
IMS T-Wave [™] velocity:	900 m/s
IMS T-Wave pulse height:	40 V
IMS duty cycle:	10.8 ms
Drift gas:	N ²

The enhanced peak capacity provided by the combination of UPLC and ion mobility separation offers some unique advantages for profiling complex matrices. It uses a combination of high resolution mass spectrometry and high efficiency ion mobility-based measurements and separations. Ion mobility spectrometry (IMS) is a rapid, orthogonal, gas phase separation technique that allows another dimension of separation to be obtained within an LC timeframe. Compounds can be differentiated based on size, shape, and charge. In addition, both precursor ion and fragment ion information can be acquired in a single acquisition for all components.

A collision cross section (CCS) value is a robust and precise physicochemical property of an ion. CCS is an important distinguishing characteristic of an ion which is related to its chemical structure and three-dimensional conformation, where the shadow of a rotating three-dimensional ion, shown in Figure 1, represents the average collision cross section. Using CCS measurements can increase targeted screening specificity. CCS measurements generated have been entered into a scientific library within UNIFI. This allows the expected and determined CCS values to be utilized in order to screen and confirm fluoroquinolone protomer formation. Here we present CCS values (derived from ion mobility drift times) as a new identification parameter, which can distinguish protomers.




Figure 1, Illustration of rotating three-dimensional conformation of an ion and average collision cross section (shadow).

Extract preparation

Extracts of porcine muscle tissue were kindly provided by RnAssays BV for the purposes of this study. Briefly, known blank porcine muscle was fortified with 25 different antimicrobial compounds (from fluoroquinolone, tetracycline, and macrolide classes) at levels the relevant to the EU MRL concentrations prior to extraction. Tissue samples were mechanically homogenized in the presence of an aqueous/organic extraction solvent followed by a centrifugation step. An aliquot of the supernatant was removed and placed in an autosampler vial for subsequent LC-MS analysis.



RESULTS AND DISCUSSION

For the assay performed, MassLynx MS data were acquired and processed with the UNIFI Scientific Information System, allowing ion mobility data to be processed in a conventional workflow for non-targeted accurate mass screening applications.

UPLC ion mobility MS has been explored as an important method development tool to support the unequivocal identification of fluoroquinolone antibiotics in crude tissue extracts. With UNIFI, it has been possible to routinely identify and characterize protomers of nine fluoroquinolones standards in a routine screening workflow.¹⁰ From the solvent standards analyzed, estimated CCS values of protomers formed for each fluoroquinolone were determined. The CCS values obtained have been incorporated into the UNIFI Scientific Library, which enabled the targeting of protomers.

The antibiotic ciprofloxacin was determined to elute at retention time 2.19 min using the generic gradient conditions employed. Figure 2 shows the base peak ion chromatogram with the UNIFI Component Plot Summary for nine of the identified fluoroquinolone antibiotics, which eluted in the region highlighted in the base peak intensity chromatogram. From review of the data using the Component Drift Plot Summary, 18 fluoroquinolone species were identified. Each fluoroquinolone is comprised of two protomers, i.e. protonation at two different sites on the molecule that have been mobility separated, as shown in Figure 3. Each retention time shows two dots on the Component Summary Drift Plot, which indicate two forms of each fluoroquinolone. The two protomers of ciprofloxacin have been highlighted. The CCS values determined are presented in the Component Summary table of Figure 4. The functionality illustrated is unique to the UNIFI Scientific Information System.




Figure 2. Base peak ion chromatogram for a mixture of 25 solvent standard antibiotic compounds, including nine fluoroquinolones. Also the Component Plot Summary is shown for 18 of the identified fluoroquinolone components between 2 and 2.6 minutes.

🥽 w	ater	s UNIFI - SYANPT G2 IMS FQ5 REIMPORT	Apr 07, 2013_1: Analysis Center					_ 8 ×
	-	🔡 👻 🚮 My Work	Nelcome to UNIFI	🙏 SYANPT G2 IMS FQS REIMP 🗙			Search folders	۵ 🗖
Rev	view	Investigate Report						
A	•	Review Results 🔹				👩 Limits 🔻 🗟 Process 🧯	Edit 🔻 🌼 Tools	🕶 🛱 🛛 💆 File 💌
hents 🛡	4	Tray: 1:6	SynaptG2_201229 [1]	Enofloxacin_1	4			Tilters 🔻
lodmo	С	omponent Drift Plot 🔻				View by	/ Retention Time	• 🖩 🍡 • 💠 👘
and C	Ite	em name: SynaptG2_20122901_039						<i>\$</i> [•] ×
Injections and Components		1	Ciprofloxac	in				•
Inje		5-	protomers					•
		4.75-						
		4.5-	Protomer 2 CCS	= 119.1Å ²	•			•
	Drift [ms]		\bigcirc	•				•
		4.25-	\cdot \bigcirc		•			
ą		4-	Protomer 1 CCS	= 108.7Å ²				
oration		3.75	. 🕑					
s Corpo		1	2.125 2.15 2.175 2.2	2.225 2.25 2.275 2.3 2	325 2.35 2.375 2.4	2,425 2,45 2,475	2.5 2.525	2.55 2.575
Waters				Retention time				
8	Adn	inistrator, UNIFI [Administrator]	ia.					Ø 🔕 🖂

4

Figure 3. UNIFI Component Summary drift plot for nine pairs of fluoroquinolone protomers.

🔽 🔡 👻 🚮 My Work		Nelcome to UNIF	T	C Explorer	🙏 SYANPT G2 IMS FQS N	OF X	Search folders	ا م
view Investigate Report								
Review Results						🙆 Limits 🔻 🗟 Process 🧃	👌 Edit 🔻 🌼 Tools	🕶 📴 🛛 🗾 File
ctions and Components 🔹 🔹 🖣	1914	Tray: 1:6		SynaptG2_201229	. [1] 🔹 🕨 👩 Ciprof	loxacin 🔹 🕨		Filters
					· · · · · · · · · · · · · · · · · · ·	Ψ		
Injections 📄 😤 🗸 🚔	Cor	mponent Summary	•			View: *Accurate Mass Scree	ning IMS REP 🖣 🚺	8 # 8
Name Type		Component n 1	m/z	Observed collision cross section (Å ²)	Collision cross section error (%)	Expected collision cross section (Å ²)	Mass error (ppm)	Expected RT (min)
SynaptG2_20120102_335	1	Ciprofloxacin	332.1402	119.10	0.08	119.00	-0.79	2.22
SynaptG2_20120102_336	2	Ciprofloxacin_1	332.1402	108.72	0.02	108.70	-0.79	2.22
SynaptG2_20120102_436	3	Danofloxacin	358.1555	124.68	-0.02	124.70	-1.68	2.34
SynaptG2_20120102_438 📩	4	Danofloxacin_1	358.1555	115.01	0.01	115.00	-1.68	2.34
SynaptG2_20122901_037 📩	5	Difloxacin	400.1467	135.06	0.00	135.06	-0.05	2.62
SynaptG2_20122901_038 📩	6	Difloxacin_1	400.1467	123.94	0.00	123.94	-0.04	2.62
SynaptG2_20122901_039 📩 🔽	7	Enofloxacin	321.1358	118.17	0.00	118.17	0.31	2.08
	8	Enofloxacin_1	321.1359	104.68	0.00	104.68	0.33	2.08
Components (SynaptG2_ 🛞 🕒	9	Enrofloxacin	360.1717	125.91	0.00	125.91	-0.27	2.40
	10	Enrofloxacin_1	360.1717	117.52	0.00	117.52	-0.29	2.40
Status Name 1 A	11	Lomefloxacin	352.1475	121.87	0.00	121.87	2.22	2.31
Ciprofloxacin	12	Lomefloxacin_1	352.1475	111.53	0.03	111.50	2.22	2.31
Ciprofloxacin_1	13	Marbofloxacin	363.1466	121.87	0.00	121.87	0.76	2.04
Danofloxacin	14	Marbofloxacin_1	363.1466	113.05	0.00	113.05	0.77	2.04
Danofloxacin_1	15	Norfloxacin	320.1401	118.04	0.00	118.04	-1.39	2.15
Difloxacin	16	Norfloxacin_1	320.1400	106.26	0.00	106.26	-1.41	2.15
Difloxacin_1	17	Sarafloxacin	386.1310	131.59	0.00	131.59	-0.24	2.58
Enofloxacin Enofloxacin 1	18	Sarafloxacin 1	386.1310	119.39	0.00	119.39	-0.24	2.58
Enofloxacin_1	•							

Figure 4. Component Plot Summary showing nine identified fluoroquinolone antibiotics and nine pairs of CCS values.

These protomer gas phase components, although they only differ with the site of protonation, have different collision cross sections. The example of ciprofloxacin is shown in Figure 5, and in this case a difference of >10 Å² (angstrom is a unit of length equal to 10–10 m, one ten-billionth of a meter), was observed in this ion mobility study.¹¹ For all fluoroquinolone protomers pairs observed, the respective difference between CCS pair values varied between 6 Å² and 12 Å² with respect to the protomer pairs. The mobility separation achieved enabled individual precursor ion and fragments of all nine fluoroquinolones to be obtained in one analysis. From a single component fragmentation spectra it was possible to determine that for ciprofloxacin, the two mobility separated species resulted from protonation taking place either on the acidic or the basic group. From method development with standards, specific CCS information was generated providing further specific information to be entered into the UNIFI scientific library. Using this information, veterinary drug residues can now be identified based on retention time, accurate mass, fragments, and CCS values. Ciprofloxacin's estimated CCS values of 108.7 Å² and 119.1 Å² have been determined. Ciprofloxacin fragments at *m/z* 314 and *m/z* 231 are shown in Figure 6. These fragments are hypothesized to form from a species where ionization has taken place on the acidic group. Fragments observed at *m/z* 288 and *m/z* 245 resulted from protonation of the basic group.




Figure 5. Mobility trace for protomers of ciprofloxacin with hypothesised respective sites of acid/basic group protonation highlighted and determined estimated CCS values.




Figure 6. Ciprofloxacin acid and basic group single component fragmentation spectra generated using a UPLC ion mobility screening workflow in UNIFI.

Once the CCS values and fragments of the individual fluoroquinolones were entered into the UNIFI scientific library, a series of spiked porcine extracts were screened to determine the presence of fluoroquinolones. Examples of the screening results are shown in Figures 7 and 8, where the identification of two protomers of danofloxacin in porcine extract are presented. Here, the benefits of ion mobility resolution and the functionality of UNIFI are demonstrated, showing the resolved protomers, as well as the removal of the matrix background from the identified component danofloxacin. It can also be seen that for both protomers, mass accuracy <1 ppm was obtained, and that the CCS error was within 2% of the expected CCS values (124.7 Å² and 115.0 Å²). The observed retention time was 2.36 min and the individual protomer precursor ion/fragmentation spectra have been obtained. This data further illustrates how confidence in true identifications can be increased when using UPLC ion mobility in conjunction with the functionality available within UNIFI Software.




Figure 7. Identification of two danofloxacin protomers identified in porcine extract, where no ion mobility resolution spectral cleanup has been selected. Precursor ion and fragmentation with matrix background ions are shown for danofloxacin protomer, expected CCS 124.7 Å².




Figure 8. Identification of two danofloxacin protomers identified in porcine extract, where ion mobility resolution spectral clean up has been selected. Precursor and fragmentation ions with matrix background ions removed, are shown for the danofloxacin protomer with expected CCS 124.70 Å². The impact of the matrix upon the gas phase intra-molecular protonation for ciprofloxacin is shown in Figure 9. The ability to routinely process ion mobility data within a workflow has made it possible to clearly observe fluctuations in the ratios of the fluoroquinolone protomers formed. As discussed, each protomer generates specific fragments, and from this data, an understanding can be obtained of why fluctuations in observed ion ratios can occur when monitoring MRM transitions.




Figure 9. Consecutive acquisitions of replicate porcine extracts showing the impact of matrix upon the gas phase intra-molecular protonation for ciprofloxacin.

Multiple protonated species have been observed for the fluoroquinolone antibiotics screened. The extent of the protonation multiplicity and its experimental variation is still being investigated. This data confirms that further consideration should be given to method development and the means of analysis chosen, since the ratio and formation of the protomers can vary with the eluent flow rate, capillary voltage, cone voltage, and matrix.

If MRM is the method of choice, consideration of the experimental conditions used and the specific transitions selected is imperative. The data presented illustrate that consistency in MRM transitions in inter/intra laboratory studies could easily be misinterpreted within and between different laboratories, and demonstrates the challenges of achieving reproducible results for these types of compounds. Ion mobility can provide a valuable tool for method development in order to ensure method robustness and consistency of results.

The benefits of UPLC ion mobility mass spectrometry can be demonstrated over traditional 'shape selective' ion mobility-based separation techniques, such as Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS). FAIMS is typically used to transmit only ions of a particular mobility, essentially acting as a filter. Using the ACQUITY UPLC I-Class System with HDMS, the fastest, ion mobility separation can be performed for all components regardless of the sample complexity, maximizing the duty cycle of the analysis and the amount of information obtained. Having a compatible duty cycle available also ensures spectral integrity is retained.

The benefits of time-of-flight mass spectrometry and historical data review (retrospective data analysis) is well known. Such historical data review is also required with ion mobility mass spectrometry. The discovery and presentation of multiple sites of protonation occurring during analysis for fluoroquinolone antibiotics can only be possible if the ion mobility data is acquired for all of the components in a sample. Continued development of the UNIFI platform's functionality has enabled routine screening using ion mobility mass spectrometry, facilitating the opportunity to develop more reproducible, repeatable, and robust assays for a wide range application areas.

CONCLUSIONS

- Separation of different intra-molecular protonated species has been achieved uniquely using ion mobility.
- Single component precursor ion and fragmentation spectra can be generated for all components simultaneously.
- Multiple sites of protonation have been identified and confirmed from the individual fragmentation spectra of each protomer species.
- CCS values can be used as an identification point in addition to retention time, precursor ion accurate mass, and accurate mass fragmentation spectra.
- Ion mobility separations can be effectively utilized to resolve analyte peaks from matrix interferences and remove the need for complex sample cleanup.
- UPLC-ion mobility mass spectrometry observations have the potential to explain the differences sometimes observed in inter-laboratory studies, where participants report results obtained from monitoring specific MRM transitions.
- The UNIFI Scientific Information System enabled the routine interrogation of UPLC ion mobility MS data acquired using the SYNAPT G2-S and SYNAPT G2-Si HDMS systems.
- Based on the observations of characteristic ionization for fluoroquinolone antibiotics included in this study, the use of UPLC ion mobility for method development purposes is warranted.

Acknowledgements

Waters kindly acknowledges Aldert Bergwerff and Wouter de Keizer (RnAssays) for the provision of the samples analyzed.

References

 M McCullagh, S Stead, J Williams, W de Keizer, A Bergwerff. Identification of Multiple Sites of Intra-Molecular Protonation and Different Fragmentation Patterns within the Fluoroquinolone Class of Antibiotics in Porcine Muscle Extracts Using Travelling Wave Ion Mobility Mass Spectrometry. Waters Applicaton Note No. <u>720004720EN</u>; June, 2013.

- E Verdon, P Couedor, B Roudaut, PJ Sandérs. Multiresidue method for simultaneous determination of ten quinolone antibacterial residues in multimatrix/multispecies animal tissues by liquid chromatography with fluorescence detection: single laboratory validation study. AOAC Inter. 2005; 88:1179–1192.
- A Kaufmann, P Butcher, K Maden, M Widmer, K Giles, D Uria. Are liquid chromatography/ electrospray tandem quadrupole fragmentation ratios unequivocal confirmation criteria? *Rapid Commun. Mass Spectrom.* 2009; 23:985–998.
- H G Mol, P Zomer, M de Koning. Qualitative aspects and validation of a screening method for pesticides in vegetables and fruits based on liquid chromatography coupled to full scan high resolution (Orbitrap) mass spectrometry. *Anal Bioanal Chem.* 2012; 403:2891–2908.
- 5. T R Croley, K D White, J H Callahan, S M Musser. The chromatographic role in high resolution mass spectrometry for non-targeted analysis. J Am Soc Mass Spectrom. 2012; 23:1569.
- 6. Commission Decision (2002/657EEC) Official Journal of the European Communities. 2002.
- Final Decision of the Commissioner, Docket # 2000N-I 571 October 24, 2000. Withdrawal of the approval of the new animal drug application for enrofloxacin in poultry. Department of Health and Human Services, U.S. Food and Drug Administration.
- 8. FDA Center for Veterinary Medicine, June 2, 1997, FDA order prohibits extra label use of fluoroquinolones and glycopeptides.
- 9. Official Journal of the European Union, L268:29–43, Regulation (EC) No 1831/2003 of the European parliament and of the council of 22 September 2003 on additives for use in animal nutrition.
- Official Journal of the European Union, L24:1–8 Annex I, Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.
- PM Lalli, BA Iglesias, HE Toma, GF de Sá, RJ Daroda, JC Silva Filho, JE Szulejko, K Araki, MN Eberlin. Protomers: formation, separation, and characterization via travelling wave ion mobility mass spectrometry. J Mass Spectrom. 2012; 47(6):712–9.



THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, UNIFI, ACQUITY, UPLC, SYNAPT, High Definition Mass Spectromety, HDMS, MassLynx, and The Science of What's Possible are registered trademarks of Waters Corporation. T-Wave is a trademark of Waters Corporation. All other trademarks are the property of their respective owners.

©2014 Waters Corporation. Produced in the U.S.A. September 2017 720005078EN AG-PDF

Waters Corporation

34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com